Court upholds Teva on BMS Baraclude generic; GSK sees good pediatric data for Promacta; Lupin unleashes generic Cipro;

@FiercePharma: Vivus hits Actavis with Qsymia patent-infringement lawsuit. Story | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes. More | Follow @TracyStaton

@EricPFierce: Biolyse is back in production with paclitaxel after a re-inspection by Health Canada cleared its plant. News | Follow @EricPFierce

@CarlyHFierce: With patent extension up for grabs, Shire agrees to test Vyvanse in preschoolers. More | Follow @CarlyHFierce

@JustinHFierce: New Pet Pace med device monitors temp and vitals, marketed for owners and vets like an e-dog-whisperer. Article | Follow @JustinHFierce

> Teva Pharmaceuticals Industries ($TEVA) said that an appeals court has upheld its challenge to the patent on Bristol-Myers Squibb's ($BMS) hepatitis B drug Baraclude and will launch its version in the U.S. as soon as it gets final approval from the FDA. Release

> GlaxoSmithKline ($GSK) reported new promising Phase II clinical data for hep C drug Promacta/Revolade in pediatric patients. Release

> Some hedge fund managers think contingent value rights could rekindle the Pfizer ($PFE), AstraZeneca ($AZN) talks but others say no. Story

> India's Lupin has begun making a generic version of Bayer's Cipro for the U.S. market and has a 180 exclusivity on the product. Story

> The U.K.'s National Health System has a new software tool to help providers determine how much access their patients have to the drugs they need. Story

> Novartis ($NVS) has come out with its pig antibiotic Florvio for swine respiratory disease, a fast-acting solution that farmers can put in their livestock's water. Release

Medical Device News

@FierceMedDev: Chrono Therapeutics snares $32M in Series A money for wearable smoking cessation device. More | Follow @FierceMedDev

@StacyALawrence: Mobile medical app brings laboratory testing to the home. Story | Follow @StacyALawrence

@MichaelGFierce: UCSB study: New silver nanoparticles dissolve if they don't hit their mark. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: C.R. Bard wins unanimous FDA panel vote for drug-eluting balloon catheter. Article | Follow @EmilyWFierce

> World's tiniest blood glucose monitor launches for iPhone, Android. More

> Medtronic scores FDA approval for TAVR in high-risk patients. Story

> With stroke of genius from a plunger, new med device cuts costs for healing wounds. Item

Biotech News

@FierceBiotech: This week's Chutes & Ladders: CEO John Johnson jumps ship as Dendreon sinks lower. Report | Follow @FierceBiotech

@JohnCFierce: I have no idea if Porges will be successful, but it's damn good fun to report on it. | Follow @JohnCFierce

@DamianFierce: Break up Amgen Pt. II: Analyst says its moonshot R&D approach is bad for business. Story | Follow @DamianFierce

@EmilyMFierce: Think tank: $4.5B investment in BRAIN Initiative too modest. More | Follow @EmilyMFierce

> With early data looming, Celgene grabs rights to Agios' leukemia drug. Story

> OncoMed hits the brakes on cancer studies after troubling safety signs. News

> Could the cunning use of CVRs save a Pfizer-AstraZeneca merger? Item

And Finally... Japanese regulators report that there were 306 violations by retailers in online sales of over-the-counter drugs in the first 24 hours after the country lifted a ban on Internet sales. Story

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.